Drug targets

PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).  The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry.  Driven by advances in cell-based phenotypic screening tools and novel […]

This is the latest episode of the free DDW podcast, “Complex problems require complex solutions”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How quantum computing can benefit drug discovery” and “Sitting down with Dr Michael Hayden from Prilenia Therapeutics”. In the first article, Brad […]

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the […]

Swedish biotech company Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.  The collaboration brings together Salipro Biotech’s services in developing stable antigens of GPCRs, ion channels and transporters via its proprietary platform, with Sanofi’s discovery programmes to identify biologics […]

In a presentation at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of technology revealed insights into cellular reservoirs of HIV and what those observations could mean for the next steps in […]

A new app note, brought to you by BellBrook Labs and supported by DDW, is available to download for free here.  Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have […]

Integrated DNA Technologies (IDT) has released Alt-R HDR Donor Blocks, a solution for increasing homology-directed repair (HDR) rates in large fragment knock-in experiments.   How does Alt-R HDR work?  The Alt-R HDR Donor Blocks incorporate advanced chemical modifications to boost the HDR rates of large genomic changes and insertions, and significantly reduce the occurrence of non-homologous […]

News round-up by DDW’s Megan Thomas for 31 January – 4 February, 2022  This week, DDW’s Megan Thomas has rounded up five stories that highlight the impact of research, breakthroughs, agreements and trials in the drug discovery world.  1. Researchers discover way to disarm potentially deadly Listeria bacteria  University of Queensland researchers have discovered a […]

A new app note, brought to you by BellBrook Labs and supported by DDW, is available to download for free here.  Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have […]

Listen to this article on the DDW Podcast: Brad Loren, Matthew Marrone, and Christopher Singer, of intellectual property and technology law firm McAndrews, Held & Malloy, on quantum computing and its benefits to drug discovery.  Explaining quantum computing and its promise  Before we explore how QC can benefit drug discovery and drug development, let us first take a […]